The OX40 ligand inhibitors market is emerging as a critical sector within the field of immuno-oncology, driven by the growing understanding of the role of OX40 (also known as CD134) in the immune system, particularly in modulating immune responses in cancer and autoimmune diseases. OX40 is a costimulatory receptor expressed on activated T cells, and its ligand (OX40L) is found on...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian